Feature
August 14, 2019
Patients with cancer who attended a molecular tumor board meeting reported higher levels of satisfaction afterward, according to study results…
Meeting News
July 30, 2019
CHICAGO —Modified FOLFOX chemotherapy plus active symptom control improved OS compared with active symptom control alone among patients with…
Meeting News
July 28, 2019
CHICAGO — An interim analysis of data from the phase 2 RAMIRIS trial suggests that a combination regimen of FOLFIRI plus ramucirumab is a…
Meeting News
July 27, 2019
CHICAGO — Administering chemotherapy 6 weeks before surgery for colon cancer was safe and reduced postoperative morbidity without adding to the…
Meeting News
July 25, 2019
CHICAGO — Pazopanib was associated with a significant improvement in PFS compared with placebo in patients with progressive carcinoid tumors…
Meeting NewsVideo
July 21, 2019
CHICAGO — Bijal D. Shah, MD, associate professor in the department of malignant hematology at Moffitt Cancer Center, spoke with HemOnc…
Meeting NewsVideo
July 20, 2019
CHICAGO — Kirk Shepard, MD, senior vice president, chief medical officer and head of global medical affairs for the oncology business group at…
Meeting News
July 17, 2019
CHICAGO — Patients with various subtypes of pretreated, metastatic sarcoma showed improved response rates and survival when treated on…
Meeting NewsVideo
July 13, 2019
CHICAGO — Max S. Topp, MD, head of hematology at University Hospital of Wuerzburg, Germany, spoke with HemOnc Today at ASCO Annual…
Meeting News
July 11, 2019
CHICAGO — The combination of pyrotinib and capecitabine significantly prolonged PFS among patients with HER2-positive metastatic breast cancer…